President Biden’s “Promoting Competition” Executive Order includes provisions to cut pharmaceutical prices including increasing imports from Canada and removing “pay for delay” deals in instances when drugs come off-patent. Supplies from Canada accounted for just 3.6% of U.S. pharmaceutical imports in the 12 months to May 31, down from 4.2% in 2017. Imports from Canada fell by 12.4% in the three months to May 31 driven by reduced shipments of anticonvulsants and immunosuppressants. Imports from India and China, which mostly represent generic drug supplier...